

Research

Open Access

Does the drug sensitivity of malaria parasites depend on their virulence?

Petra Schneider*^{1,2}, Brian HK Chan^{1,3}, Sarah E Reece^{1,2} and Andrew F Read^{1,3}

Address: ¹Institutes of Evolution, Immunology and Infection Research, University of Edinburgh, EH9 3JT, UK, ²Centre for Immunity, Infection and Evolution Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, EH9 3JT, UK and ³Center for Infectious Disease Dynamics, Department of Biology, Mueller Laboratory, the Pennsylvania State University, University Park, PA 16802, USA

Email: Petra Schneider* - petra.schneider@ed.ac.uk; Brian HK Chan - bhc12@psu.edu; Sarah E Reece - sarah.reece@ed.ac.uk; Andrew F Read - a.read@psu.edu

* Corresponding author

Published: 16 December 2008

Received: 6 August 2008

Malaria Journal 2008, **7**:257 doi:10.1186/1475-2875-7-257

Accepted: 16 December 2008

This article is available from: <http://www.malariajournal.com/content/7/1/257>

© 2008 Schneider et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Chemotherapy can prompt the evolution of classical drug resistance, but selection can also favour other parasite traits that confer a survival advantage in the presence of drugs. The experiments reported here test the hypothesis that sub-optimal drug treatment of malaria parasites might generate survival and transmission advantages for virulent parasites.

Methods: Two *Plasmodium chabaudi* lines, one derived from the other by serial passage, were used to establish avirulent and virulent infections in mice. After five days, infections were treated with various doses of pyrimethamine administered over 1 or 4 days. Virulence measures (weight and anaemia), parasite and gametocyte dynamics were followed until day 21.

Results: All treatment regimes reduced parasite and gametocyte densities, but infections with the virulent line always produced more parasites and more gametocytes than infections with the avirulent line. Consistent with our hypothesis, drug treatment was disproportionately effective against the less virulent parasites. Treatment did not affect the relative transmission advantage of the virulent line. Neither of the lines contained known mutations conferring classical drug resistance.

Conclusion: Drug-sensitivity of malaria parasites can be virulence-dependent, with virulent parasites more likely to survive sub-optimal treatment. If this proves to be general for a variety of drugs and parasite species, selection imposed by sub-optimal drug treatment could result in the evolution of more aggressive malaria parasites.

Background

Patients in endemic areas often carry malaria parasites while having levels of antimalarial drugs in their blood that fail to eliminate all parasites. This can be due to the presence of residual levels of drugs when a new infection is acquired [1,2], because recommended treatment could not clear all parasites [3-6] or because of inadequate treat-

ment (for example from low quality drugs [7,8] or poor compliance). Due to variable metabolic drug uptake [9,10], recommended doses may not be adequate for all sub-groups, such as children or pregnant women [4,11,12]. Even during supervised treatment with potent and high quality drugs, including artemisinin-based combination therapies, patients can be cured from disease

symptoms but low numbers of parasites to survive and transmit [5,13,14]. In all these cases, drugs are not maintained at sufficient doses for long enough to kill all parasites.

Exposure of parasites to sub-optimal drug levels can facilitate the evolution of classical drug resistance, where resistant parasites survive drug treatment through well-studied mechanisms, such as target-site mutations and detoxification or efflux pathways [15]. In what follows, such mechanisms are referred to as 'classical drug resistance'. However, genetically-encoded parasite traits other than classical resistance could also influence survival in drug-treated infections [16-20] and, hence, be subject to drug-induced selection pressures. For instance, malaria parasites vary in virulence (the harm caused to hosts as a consequence of infection) [21-23], the molecular basis of which is beginning to be understood [24-26]. Here it is proposed that virulence affects drug sensitivity. For instance, in some cases, parasite lines which replicated rapidly or which can persist at higher densities for longer are associated with more severe disease (virulence) [21,27,28]. This could make them less vulnerable to drug treatment if they can rapidly recover high parasite densities after a bout of drug-induced mortality. Alternatively, rapid replication could render parasites more vulnerable to metabolic disruption and thus, greater drug-induced mortality. In either case, the evolution of higher or lower virulence could be a consequence of drug-induced selection. Testing whether a given drug regime has differential effects on virulent and avirulent parasites is the first key

step in testing the hypothesis that chemotherapy has the potential to impose selection for parasite traits other than those involved in classical resistance (Figure 1). Such selection processes may be occurring in the field but are difficult to study due to various confounding factors, including the presence of multiple, interbreeding parasite genotypes. Therefore, *in vivo* experiments using an animal model were designed to test if sensitivity to drug treatment can be virulence-dependent.

Methods

Terminology

Drug resistance

The WHO defines drug resistance as "the ability of a parasite strain to survive or multiply in the presence of drug concentrations that normally destroy parasites of the same species or prevent their multiplication, provided that the drug was properly absorbed and parasites exposed to it" [29]. This definition includes all parasite traits that affect the survival or transmission of parasites exposed to drugs. Drug resistance in malaria is acquired through selection of mutants that are favoured under conditions of drug exposure. This includes mutations directly related to the action of the drug ('classical drug resistance'), but also other parasite traits that, directly or indirectly, may confer a survival and transmission advantage in the presence of drugs (non-classical drug resistance). As was hypothesised above, parasite replication rate could be an example of such a non-classical resistance trait, whereas target site mutations, and efflux and detoxifica-




Figure 1

Possible outcomes for the relation between drug sensitivity and virulence. Without drug treatment (black symbols), infections with the virulent parasite line (Vir) produce more parasites compared to the avirulent line (Avir). If both lines are affected similarly by drug treatment (open symbols), the proportionate difference between them will be unaffected by drug treatment (1A). If the virulent line is less sensitive to drug treatment, the reduction in parasite numbers will be disproportionately greater for the avirulent line (1B). If the virulent line is more sensitive to drug treatment, the reduction in parasite numbers will be disproportionately greater for the virulent line (1C).

tion mechanisms are examples of classical resistance. Non-classical drug resistance is the subject of this study.

Sub-curative vs. sub-optimal

Ideally, drug treatment achieves two things: restoration of patient health and clearance of parasites. In the literature, the term 'cure' is used variably to refer to either or both of these outcomes. Therefore, the term 'sub-curative drug-treatment' is ambiguous. For clarity, the term 'sub-optimal drug-treatment' is used here and specifically defined as drug treatment that allows classically drug-sensitive parasites to survive, with or without eliminating disease symptoms.

Experimental overview and rationale

Here, the first experimental tests of how genetically related parasites, differing in virulence, perform under a range of drug treatment regimes are presented. It is well known that serial passage increases parasite virulence [30,31]. This makes it possible to derive parasites, which differ in virulence but come from the same clonal lineage. Thus, the effect of chemotherapy on asexual- and transmission-stage densities can be tested on genetically similar parasites differing in virulence. To mimic the possible causes of sub-optimal treatment that can occur in the field (reviewed in the Introduction), parasites were challenged with sub-optimal doses and sub-optimal duration of drug treatment when symptoms first appeared.

Parasites

The original *Plasmodium chabaudi* isolate was obtained from a thicket rat from the Central African Republic [32]. Genotype CW_{avir} (CW175) was obtained after cloning of the wild isolate and 4 passages in mice. CW_{vir} (CW202) was derived from CW_{avir} by 11 serial passages in mice [30] and became more virulent in the process [33]. Samples of CW_{avir} and CW_{vir} were passaged a further three times in C57Bl/6J mice before the experiments described here. None of the parasite lines involved, nor any of their ancestors had been exposed to antimalarial drugs prior to these experiments.

Experimental set-up

Drug sensitivity to the antimalarial drug pyrimethamine was tested *in vivo* using 6–10 week old C57Bl/6J female mice (Harlan), with access to food (41B maintenance diet, Harlan) and drinking water supplemented with 0.05% para-amino benzoic acid [34] *ad libitum*. Mice were infected with 10⁵ parasites of either CW_{vir} or CW_{avir} by intraperitoneal injection and given treatment with the antimalarial drug pyrimethamine from day 5 after infection, when first symptoms of disease occurred. The experimental setup is shown in Table 1. Pyrimethamine was administered during four consecutive days in experiment 1 (five mice per group) and experiment 2 (four mice per

Table 1: Treatment groups and sample sizes for experiments 1, 2 and 3

Days	Dose	Nr mice exp 1		Nr mice exp 2	
		CW _{avir}	CW _{vir}	CW _{avir}	CW _{vir}
4	0	5	5*	4	4#
4	1	5	5**	4	4
4	3	5	5	4	4
4	5	5	5§	4	4
Nr mice exp 3					
Days	Dose	CW _{avir}	CW _{vir}		
1	0	4	4		
1	4	4	4		
1	8	4	4		
1	12	4	4		
1	20	4	4		

Days: duration of pyrimethamine treatment in days, starting from day 5 after infection. Dose: mg/kg/day. Nr mice: sample sizes for each group, with sample sizes for each experiment. * Each symbol indicates a mouse excluded from analysis, euthanized early in the experiment because of severe anaemia. § 1 mouse excluded, no parasites detected at time of treatment. # 4 mice euthanized on d11 and d12 after infection, data have been used where possible.

group) at doses of 0, 1, 3 and 5 mg/kg or, in experiment 3, on a single day at doses of 0, 4, 8, 12 or 20 mg/kg (four mice per group). In experiment 1, four mice infected with CW_{vir} were excluded from analysis, three of these were severely anaemic and had to be euthanized early in the experiment (dose 0, n = 1; dose 1, n = 2) and parasites were not detected at time of treatment in another mouse (dose 5; Table 1). In experiment 2, all four mice in the untreated CW_{vir} group had to be euthanized a few days after the peak of infection on day 11 (n = 1) or 12 (n = 3), and available data have been used in the analysis unless indicated otherwise. Pyrimethamine was dissolved in dimethyl sulphoxide at the required concentration and injected intraperitoneally with a maximum total volume of 50 µL. To monitor treatment efficacy, parasite dynamics and virulence (weight loss, anaemia) were followed until three weeks post infection, when mice no longer show disease symptoms. Asexual parasites were counted per 1000 RBCs by examination of Giemsa-stained thin smears from tail bleeds. Red blood cell density was determined by flow cytometry (Beckman Coulter) and used to calculate parasite density/mL of blood. Blood samples for RNA (10 µL) and DNA (5 µL) extraction were stored to quantify gametocytes by quantitative reverse-transcriptase PCR and for sequencing to detect pyrimethamine resistance mutations.

Nucleic acid extraction and PCR analysis of gametocytes

Ten µL blood samples were added to 30 µL nucleic acid purification lysis solution (Applied Biosystems) and 15 µL PBS, gently mixed and stored at -80°C. RNA was extracted using the ABI Prism 6100® [35] and cDNA was

obtained by reverse transcriptase PCR (high capacity cDNA archive kit, Applied Biosystems) according to manufacturer's protocols. Gametocytes were counted using quantitative real-time PCR with primers based on the gametocyte-specifically expressed gene PC302249.00.0 [36].

During qPCR analysis for gametocyte quantification, three different dilution series of positive control samples, initiated from different mice with *P. chabaudi* gametocytes, were tested in concentrations ranging from 7 to 7×10^6 gametocytes/mL. The average threshold cycle (Ct) values ± 1 standard deviation are shown in Figure 2. Gametocyte numbers have a high correlation to Ct values ($R^2 = 0.99$; $p < 0.0001$). The absolute detection limit for the assay was determined to be at least 700 gametocytes/mL of blood. Lower gametocyte densities were detected in 88% (221 gametocytes/mL), 67% (71/mL), 43% (22/mL) and 12% (7/mL) of the tested control samples. This decline in probability of detection is most likely related to the probability of target nucleic acid being present in the 10 μ L blood sample.

Classical drug resistance genotyping

Pyrimethamine is an antifolate drug that inhibits the enzyme dihydrofolate reductase (DHFR) that is essential in the folic acid pathway, ultimately leading to pyrimidine synthesis. Pyrimethamine inhibits parasite multiplication but does not directly kill gametocytes. As with other malaria parasite species, resistance to pyrimethamine in *P. chabaudi* is conferred by point mutations in the *dhfr* gene, resulting in conformational changes of the enzyme and decreased binding capacity of the drug [37,38]. Samples from the day of infection and day 21 were analysed to detect resistance mutations in the *dhfr* gene, using the following protocol. DNA was extracted using InstaGene Matrix (BioRad) according to the standard protocol for DNA preparation from whole blood. The extracted DNA, forward primer pcdhfr-10 5'-GCTATTTCITTTCTACATTTGC-3' and reverse primer pcdhfr-11 5'-TTTAAATGATGAGCATGCTC-3' were used to amplify the region of the *dhfr* gene that contains possible mutations involved in pyrimethamine resistance. The PCR reaction included 13.75 μ L water, 10 μ L 5 \times PCR buffer (Promega), 3 μ L 25 mM MgCl₂, 1 μ L dNTPs 10 mM, 0.25 μ L Taq 5 u/ μ L, 1 μ L of each primer 10 μ M and 20 μ L DNA sample. The tem-




Figure 2
PCR quantification of *P. chabaudi* gametocytes. Average threshold value (Ct) \pm standard deviation for *P. chabaudi* gametocyte control samples tested in 25 different 96-well plates for quantitative PCR.

perature programme used for amplification was 95°C for 60 seconds, then 30 cycles of each 95°C for 60 seconds, 52°C for 60 seconds, 65°C for 60 seconds and ending with 65°C for 600 seconds and storage at 4°C. PCR products were purified using Qiaquick PCR purification kit (Qiagen Ltd. UK) according to manufacturer's protocol and sequenced.

Statistics

The maximum and cumulative measures of parasite and gametocyte density achieved by each infection during the 21-day experiments were used as response variables in the analysis. *Plasmodium chabaudi* has a cell-cycle of approximately one day for asexual parasites, therefore, cumulative parasite density is a measure of the total number of parasites present during a defined period of the infection. Gametocyte density correlates positively with infectivity to mosquitoes [21,39] and, when summed over the course of an infection, provides a measure of transmission potential. Cumulative parasite and gametocyte counts were \log_{10} -transformed to meet assumptions of normality and homogeneity of variance. Analyses were performed using general linear models in SPSS version 14.0 (SPSS Inc., Chicago, USA). Full models for analysis of parasite data included the main effects of clone (CW_{avir} or CW_{vir} ; virulence classification) and dose, their 2-way interaction, experiment (1–3) as a random factor, and the covariates weight and anaemia at the day of infection as well as parasite density at the start of treatment. The clone \times dose interaction indicates that CW_{vir} and CW_{avir} were differentially affected by drug dose, the hypothesis under test (Figure 1). Models were minimized using step-wise deletion.

Results

Virulence of ancestral and derived parasites in the absence of drug-treatment

As found previously [33], CW_{vir} was indeed more virulent in the absence of chemotherapy, generating greater weight loss and anaemia than CW_{avir} (Figure 3; mean difference \pm s.e. of maximum weight loss: $15 \pm 2\%$ of starting body mass; $F_{1,21} = 68.6$, $p < 0.001$; mean difference \pm s.e. $12 \pm 2\%$ of starting RBC density; $F_{1,21} = 47.9$, $p < 0.001$).

Asexual parasites

In the absence of drugs, CW_{vir} achieved higher maximum asexual parasite densities than CW_{avir} (mean difference \pm s.e. $9.9 \pm 2.5 \times 10^8$, $F_{1,21} = 21.5$, $p < 0.001$). Drug treatment reduced maximum asexual parasite density and delayed peak parasite density in a dose-dependent manner (Figure 4). At all doses, cumulative asexual parasite density was reduced by drug treatment (dose effect, $F_{7,90} = 58.9$, $p < 0.0001$), but remained significantly higher in CW_{vir} than CW_{avir} infections (Figure 5; clone effect, $F_{1,90} = 153.4$, $p < 0.0001$). The relative reduction in parasites densities induced by the different doses differed between the CW_{vir} and CW_{avir} (clone \times dose interaction $F_{7,90} = 3.6$, $p = 0.002$),

with the impact disproportionately greater on CW_{avir} . Thus, sub-optimal chemotherapy enhanced the relative difference in cumulative parasite densities between the two clonal lineages (Figure 5).

Gametocytes

In the absence of drug treatment, CW_{vir} infections had higher peak gametocyte densities (mean difference \pm s.e. $34.4 \pm 12.8 \times 10^6$, $F_{1,19} = 7.3$, $p = 0.014$) as well as higher total gametocyte production (Figure 6; $F_{1,15} = 30.9$, $p < 0.001$) than CW_{avir} infections.

Total gametocyte numbers were significantly reduced by treatment (dose effect, $F_{7,82} = 16.0$, $p < 0.001$) and the higher transmission potential for CW_{vir} is generally maintained under conditions of drug treatment (clone effect $F_{1,82} = 51.7$, $p < 0.001$).

Overall the experiments, the effect of drug treatment on the two parasite lines was marginally different (clone \times dose interaction $F_{7,82} = 2.1$, $p = 0.06$). However, breaking these data down by experiment showed that there was no general pattern (Figure 6). Gametocyte densities in the third experiment, which involved one day of treatment show similar patterns (Figure 6C) to those seen in the asexual densities (Figure 5), but the disproportionate reductions in transmission potential of CW_{avir} at the higher doses was not statistically significant (clone \times dose $F_{4,17} = 1.62$, $p = 0.196$). Due to loss of data for the untreated CW_{vir} group in experiment 2 (see Methods), it is not possible to determine the differences in transmission potential between the two lines in the absence of treatment (Figure 6B). Among the remaining (treated) groups, the different doses had similar effects on both CW_{vir} and CW_{avir} (clone \times dose $F_{2,20} = 0.11$, $p = 0.901$). In experiment 1, the clone differences did vary with treatment (clone \times dose $F_{3,24} = 9.45$, $p < 0.001$), but inspection of Figure 6A shows that chemotherapy is causing similar proportionate reductions in gametocyte numbers for both lines except at an intermediate dose, which was disproportionately effective against CW_{vir} (or ineffective against CW_{avir}). The cause for this effect is unknown and it was not observed in the repeat experiment (Figure 6B).

Dhfr mutations

Mutations known to confer resistance to the drug pyrimethamine in *P. chabaudi* [37,38] in parasites of either clonal lineages were not observed, either at the start of the infections, or among parasites surviving treatment and present on day 21 post-infection, the last day of the experiment.

Discussion

In this study, the drug sensitivity of two parasite lines, one derived from the other by serial passage [30] were compared. The virulent derived line was significantly less sen-




Figure 3
Infections with CW_{vir} resulted in greater weight loss and red blood cell loss than CW_{avir}. Virulence measures for *P. chabaudi* CW_{avir} and CW_{vir} without drug treatment. Mean ± s.e. values over 13 (CW_{avir}) and 12 (CW_{vir}) infections combined for experiments 1, 2 and 3 are shown. Statistical difference between lines after adjustment for between-experiment differences (experiment) are at 0.001 level (**).

sitive to sub-optimal pyrimethamine treatment (Figures 4 and 5). This decreased sensitivity to pyrimethamine was not associated with the presence at detectable levels of mutations known to confer classical drug resistance [37,40]. Because of this, and because these parasite lines had never previously been exposed to pyrimethamine and because possible between-host variation in immune response and bioavailability have been controlled for by using inbred hosts, these data provide evidence for 'non-classical' drug resistance in malaria parasites.

These data raise several potentially important questions. First, is the differential susceptibility to drugs due to parasite factors associated with virulence? Higher parasite densities at the time of treatment could be associated with both virulence and the ability to recover from sub-optimal chemotherapy [17-20]. However, parasite density at time of treatment was included as a covariate in all analyses

and it is therefore unlikely that higher parasite densities *per se* are responsible for the patterns reported. Clearly, with a comparison of two lines, it is not possible to attribute the cause of the differential susceptibility to any specific difference between CW_{vir} and CW_{avir}. Nonetheless, these two lines have almost identical genotypes and the most obvious difference between them is that the derived line is more virulent. Establishing whether virulence is responsible for the 'non-classical drug resistance' observed requires more data.

Second, could sub-optimal chemotherapy impose selection in favour of more virulent parasites? Subject to the normal cautions about generalizing from animal models (reviewed in this context by Wargo *et al* [41]), these data suggest it could. The avirulent parasites were disproportionately suppressed (Figure 5), implying that within-host selection imposed by drug pressure will favour virulent




Figure 5
Effects of pyrimethamine treatment on total asexual parasite density during an infection. Total asexual parasites/mL blood summed for days 6–21 after treatment \pm standard error. PYR0 = no drug, PYR1, 3, 4, 5, 8, 12 and 20 indicate daily doses of pyrimethamine in mg/kg. 5A: experiments 1 and 2 combined. 5B: Experiment 3.

nario, it is host death that restrains the evolution of ever more virulent parasites. A logical consequence of this view is that interventions which keep hosts alive reduce this restraining force, while still allowing parasites to benefit from the transmission rewards of increasing their virulence. Thus life-protecting interventions have the potential to allow more virulent strains to circulate in malaria populations [49]. This hypothesis is supported by observations that virulence increases with serial passage [30,31], and theoretical analysis of the evolutionary consequences of vaccination [50-52] or chemotherapy [53,54] predict virulence to increase. If sub-optimal drug treatment reduces the costs of virulence (hypothesized) as well as conferring a survival advantage on virulent parasites (as the data reported here indicate), chemotherapy could be a potent force for the evolution of more virulent parasites.

These ideas and the data reported here, raise several questions that could be explored theoretically. First, will there be positive feedback, whereby the frequency of sub-optimally treated infections will rise as the virulent parasites favoured by sub-optimal therapy become more common? Can this process be halted by increasing drug doses? Second, combination therapy is now recommended by the WHO because it reduces the probability that classical drug-resistance mutations can emerge in the first place. By preventing classical resistance from arising, is combination therapy making virulence evolution more likely? There will almost certainly already be standing genetic variation in virulence in nature on which selection can act.

Third, will classical resistance, when it does arise, be more likely to appear in more virulent parasites? Fourth, could virulence-related susceptibility to drugs act as a form of cross-resistance which continue to protect parasites when policy switches to new drugs after failure of current combinations? The preliminary data reported here, are obviously far from the final word, but given the potential importance of the problem, these preliminary data strongly argue for further investigation of questions like these, and of course further empirical investigation of the phenomenon of virulence-mediated drug sensitivity.

Conclusion

Virulent parasites were disproportionately less susceptible to sub-optimal drug treatment than were less virulent parasites. It is important to determine whether virulence-dependent drug sensitivity occurs across a variety of drugs, treatment regimes and parasite species. If it does, selection imposed by sub-optimal drug treatment could cause the evolution of more virulent parasites, rendering future infections more aggressive.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PS designed the study, collected, analysed and interpreted the data and drafted the manuscript. BC assisted in data collection. SR and AR assisted in conception of the study, interpretation of data and drafting the manuscript. All authors read and approved the final manuscript.




Figure 6
Effects of pyrimethamine treatment on total gametocyte density during an infection. Total gametocytes/mL blood \pm s.e. summed over the duration of infection. PYR0 = no drug, PYR1, 3, 4, 5, 8, 12 and 20 indicate daily doses of pyrimethamine in mg/kg. Figure 6A and B. 4-day treatment experiments 1 and 2, summed for days 6–21. Data for the untreated CW_{vir} group is missing as a result of host death on days 11 and 12. Figure 6C. Experiment 3, 1-day treatment, summed for days 6–19.

Acknowledgements

We thank M. Mackinnon for parasites, P. Hunt for providing primers and protocols used to genotype the *dhfr* gene of our parasites, and the Wellcome Trust and the BBSRC for funding.

References

1. Watkins WM, Mosobo M: **Treatment of *Plasmodium falciparum* malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life.** *Trans R Soc Trop Med Hyg* 1993, **87(1)**:75-78.
2. White NJ: **The assessment of antimalarial drug efficacy.** *Trends in Parasitology* 2002, **18**:458-464.
3. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, Group IAS: **Artesunate combinations for treatment of malaria: meta-analysis.** *Lancet* 2004, **363**:9-17.
4. Barnes KI, Lindgardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randerianarivelosoa M, Gbotosho GO, Watkins WM, Sibley CH, White NJ: **World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology.** *Malaria Journal* 2007, **6**:122.
5. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JJ, Ord R, Sutherland CJ, Omar SA, Sauerwein RW: **Moderate effect of artemisinin-based combination therapy on transmission of *Plasmodium falciparum*.** *Journal of Infectious Diseases* 2006, **193**:1151-1159.
6. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJM: **Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial.** *Lancet* 2005, **365**:1474-1480.
7. Bate R, Coticelli P, Tren R, Attaran A: **Antimalarial drug quality in the most severely malarious parts of Africa – a six country study.** *PLoS One* 2008, **3**:e2132.
8. Dondorp AM, Newton PN, Mayxay M, Damme Wv, Smithuis FM, Yeung S, Petit A, Lynam AJ, Johnson A, Hien TT, McGready R, Farrar JJ, Looareesuwan S, Day NPJ, Green MD, White NJ: **Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials.** *Trop Med Int Health* 2004, **9(12)**:1241-1246.
9. Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Bras JI, Deloron P: **Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating *Plasmodium falciparum* malaria in Gabonese children.** *Antimicrob Agents Chemother* 2003, **47(1)**:231-237.
10. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S, White NJ: **Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria.** *Antimicrob Agents Chemother* 2003, **47(11)**:3458-3463.
11. Terlouw DJ, Courval JM, Kolczak MS, Rosenberg OS, Oloo AJ, Kager PA, Lal AA, Nahlen BL, Kuile FO: **Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya.** *Journal of Infectious Diseases* 2003, **187**:467-476.
12. Terlouw DJ, Nahlen BL, Courval JM, Kariuki SK, Rosenberg OS, Oloo AJ, Kolczak MS, Hawley WA, Lal AA, Kuile FO: **Sulfadoxine-Pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing.** *Antimicrob Agents Chemother* 2003, **47(9)**:2929-2932.
13. Schneider P, Bousema JT, Gouagna LC, Otieno S, Vegte-Bolmer Mvd, Omar SA, Sauerwein RW: **Submicroscopic *Plasmodium falciparum* gametocyte densities frequently result in mosquito infection.** *Am J Trop Med Hyg* 2007, **76(3)**:470-474.
14. Sutherland CJ, Ord R, Duno S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GA: **Reduction of malaria transmission to *Anopheles* mosquitoes with a six-dose regimen of co-artemether.** *PLoS Medicine* 2005, **2**:e92.
15. White NJ: **Drug resistance in malaria.** *British Medical Bulletin* 1998, **54**:703-715.
16. White NJ: **Why is it that antimalarial drug treatments do not always work?** *Annals of Tropical Medicine and Parasitology* 1998, **92**:449-458.
17. Nakazawa S: ***Plasmodium berghei* NK 65: Studies on the effect of treatment duration and inoculum size on recrudescence.** *Experimental Parasitology* 2005, **111**:59-63.
18. Nakazawa S, Kanbara H, Aikawa M: **Recrudescence of *Plasmodium falciparum* in culture: Unaffectedness and frequency of dormant parasites.** *Journal of Experimental Clinical Medicine* 1998, **23**:99-100.
19. Nakazawa S, Maoka T, Uemura H, Ito Y, Kanbara H: **Malaria parasites giving rise to recrudescence in vitro.** *Antimicrob Agents Chemother* 2002, **46(4)**:958-965.
20. Thapar MM, Gil JP, Björkman A: **In vitro recrudescence of *Plasmodium falciparum* parasites suppressed to dormant state by atovaquone alone and in combination with proguanil.** *Trans R Soc Trop Med Hyg* 2005, **99(1)**:62-70.
21. Mackinnon MJ, Read AF: **Genetic relationships between parasite virulence and transmission in the rodent malaria *Plasmodium chabaudi*.** *Evolution* 1999, **53**:689-703.
22. Yoeli M, Hargreaves B, Carter R, Walliker D: **Sudden increase in virulence in a strain of *Plasmodium berghei yoelii*.** *Ann Trop Med Parasitol* 1975, **69(2)**:173-178.
23. Covell G, Nicol WD: **Clinical, chemotherapeutic and immunological studies on induced malaria.** *British Medical Bulletin* 1951, **8**:51-58.
24. Cockburn IA, Mackinnon M, O'Donnell A, Allen SJ, Moulds JM, Baisor M, Bockarie M, Reeder JC, Rowe JA: **A human complement receptor one polymorphism that reduces *Plasmodium falciparum* rosetting confers protection against severe malaria.** *Proceedings of the National Academy of Sciences of the United States of America* 2004, **101**:272-277.
25. Kaestli M, Cockburn IA, Cortés A, Baea K, Rowe JA, Beck HP: **Virulence of malaria is associated with differential expression of *Plasmodium falciparum* var gene subgroups in a case-control study.** *Journal of Infectious Diseases* 2006, **193**:1567-1574.
26. Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Koné A, Diallo DA, Raza A, Kai O, Marsh K, Plowe CV, Doumbo OK, Moulds JM: **Blood group O protects against severe *Plasmodium falciparum* malaria through the mechanism of reduced rosetting.** *Proceedings of the National Academy of Sciences of the United States of America* 2007, **104**:17471-17476.
27. Chotivanich K, Udomsangpetch R, Simpson JA, Newton P, Pukrittayakamee S, Looareesuwan S, White NJ: **Parasite multiplication potential and the severity of falciparum malaria.** *Journal of Infectious Diseases* 2000, **181**:1206-1209.
28. Deans AM, Lyke KE, Thera MA, Plowe CV, Koné A, Doumbo OK, Kai O, Marsh K, Mackinnon MJ, Raza A, Rowe JA: **Low multiplication rates of African *Plasmodium falciparum* isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence.** *Am J Trop Med Hyg* 2006, **74(4)**:554-563.
29. WHO: **Guidelines for the treatment of malaria.** WHO/HTM/MAL/2006/108 ISBN 978 92 4 154694 2 2006:266.
30. Mackinnon MJ, Read AF: **Selection for high and low virulence in the malaria parasite *Plasmodium chabaudi*.** *Proc Biol Sci* 1999, **266(1420)**:741-748.
31. Ebert D: **Experimental evolution of parasites.** *Science* 1998, **282**:1432-1436.
32. Beale GH, Carter R, Walliker D: **Genetics.** In *Rodent Malaria* Edited by: Killick-Kendrick R, Peters W. London: Academic Press; 1978:213-245.
33. Mackinnon MJ, Gaffney DJ, Read AF: **Virulence in rodent malaria: host genotype by parasite genotype interactions.** *Infect Genet Evol* 2002, **1(4)**:287-296.
34. Jacobs RL: **Role of p-aminobenzoic acid in *Plasmodium berghei* infection in the mouse.** *Experimental Parasitology* 1964, **15**:213-225.
35. Wargo AR, Randle N, Chan BHK, Thompson J, Read AF, Babiker HA: ***Plasmodium chabaudi*: Reverse transcription PCR for the detection and quantification of transmission stage malaria parasites.** *Experimental Parasitology* 2006, **112**:13-20.
36. Wargo AR, de Roode JC, Huijben S, Drew DR, Read AF: **Transmission stage investment of malaria parasites in response to in-host competition.** *Proc Biol Sci* 2007, **274(1625)**:2629-2638.

37. Cheng Q, Saul A: **The dihydrofolate reductase domain of rodent malaria: point mutations and pyrimethamine resistance.** *Mol Biochem Parasitol* 1994, **65(2)**:361-363.
38. Cowman AF, Foote SJ: **Chemotherapy and drug resistance in malaria.** *International Journal for Parasitology* 1990, **20**:503-513.
39. Taylor LH, Read AF: **Why so few transmission stages? Reproductive restraint by malaria parasites.** *Parasitology Today* 1997, **13**:135-140.
40. Peterson DS, Walliker D, Wellem TE: **Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.** *Proceedings of the National Academy of Sciences of the United States of America* 1988, **85**:9114-9118.
41. Wargo AR, Huijben S, Roode JCD, Shephard J, Read AF: **Competitive release and facilitation of drug-resistance parasites after therapeutic chemotherapy in a rodent malaria model.** *Proceedings of the National Academy of Sciences of the United States of America* 2007, **104**:19914-19919.
42. Reece SE, Drew DR, Gardner A: **Sex ratio adjustment and kin discrimination in malaria parasites.** *Nature* 2008, **453**:609-614.
43. Paul REL, Coulson TN, Raibaud A, Brey PT: **Sex determination in malaria parasites.** *Science* 2000, **287**:128-131.
44. Buckling A, Read AF: **The effect of partial host immunity on the transmission of malaria parasites.** *Proc Biol Sci* 2001, **268(1483)**:2325-2330.
45. Paul RE, Bonnet S, Boudin C, Tchuinkam T, Robert V: **Aggregation in malaria parasites places limits on mosquito infection rates.** *Infect Genet Evol* 2007, **7(5)**:577-586.
46. Buckling AG, Taylor LH, Carlton JM, Read AF: **Adaptive changes in Plasmodium transmission strategies following chloroquine chemotherapy.** *Proc Biol Sci* 1997, **264(1381)**:553-559.
47. Buckling A, Ranford-Cartwright LC, Miles A, Read AF: **Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro.** *Parasitology* 1999, **118**:339-346.
48. Buckling AGJ, Read AF: **The effect of chloroquine treatment on the infectivity of Plasmodium chabaudi gametocytes.** *International Journal for Parasitology* 1999, **29**:619-625.
49. Mackinnon MJ, Gandon S, Read AF: **Virulence evolution in response to vaccination: The case of malaria.** *Vaccine* 2008, **26**:C42-C52.
50. Gandon S, Mackinnon MJ, Nee S, Read AF: **Imperfect vaccines and the evolution of pathogen virulence.** *Nature* 2001, **414**:751-756.
51. Gandon S, Mackinnon M, Nee S, Read A: **Imperfect vaccination: some epidemiological and evolutionary consequences.** *Proc Biol Sci* 2003, **270(1520)**:1129-1136.
52. Mackinnon MJ, Read AF: **Immunity promotes virulence evolution in a malaria model.** *PLoS Biology* 2004, **2**:E230.
53. Porco TC, Lloyd-Smith JO, Grossa KL, Galvani AP: **The effect of treatment on pathogen virulence.** *Journal of Theoretical Biology* 2005, **233**:91-102.
54. Galvani AP: **Epidemiology meets evolutionary ecology.** *Trends in Ecology and Evolution* 2003, **18**:132-139.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

